Uterine Cancer Study Act of 2024

HR 9782, the Uterine Cancer Study Act of 2024, directs the U.S. Department of Health and Human Services (HHS) to study whether hair straighteners - specifically chemical products - may be linked to uterine cancer, with a focus on higher rates among women of color. The study will review existing research, examine impacts across racial and ethnic groups, and break down results by product type (e.g., dyed, bleached, or permed straighteners). HHS must submit a study methodology within 45 days of the bill’s enactment and complete the study, reporting findings to Congress within two years. The bill does not impose new regulations but may inform future FDA safety requirements for hair straightening products. This affects women of color disproportionately impacted by uterine cancer and the broader population using such products.